16 citations
,
May 2019 in “International Journal of Women's Dermatology”
The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeedingwomen, but more data is needed on the risks of many dermatologic drugs.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Many are unaware of effective male pattern baldness treatments like finasteride and minoxidil, often opting for ineffective remedies. Educating others on proven treatments and potential side effects is crucial.
Concerns about finasteride affecting sperm quality and embryo abnormalities during IVF. The user plans to stop finasteride for 6 months and use minoxidil, microneedling, a red light cap, and saw palmetto shampoo to manage hair loss.
A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.
The conclusion of this conversation about hair loss is that genetics play a significant role in determining hair loss, and specific treatments like finasteride may not be effective against certain compounds like masteron and trenbolone.